Cassava Sciences, Inc. (SAVA) |
| 2.145 0.095 (4.63%) 01-14 13:15 |
| Open: | 2.08 |
| High: | 2.19 |
| Low: | 2.075 |
| Volume: | 514,377 |
| Market Cap: | 104(M) |
| PE Ratio: | -0.97 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 3.32 |
| Resistance 1: | 2.80 |
| Pivot price: | 2.12 |
| Support 1: | 1.96 |
| Support 2: | 1.63 |
| 52w High: | 4.98 |
| 52w Low: | 1.15 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Financials
| EPS | -2.220 |
| Book Value | 1.690 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.896 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -24.8 |
| Return on Equity (ttm) | -85.4 |
Company news
Wed, 24 Dec 2025
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Tue, 23 Dec 2025
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Tue, 23 Dec 2025
Cassava Closes Chapter On Investor Lawsuit With Around $31 Million Deal - Sahm
Tue, 23 Dec 2025
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Tue, 23 Dec 2025
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Tue, 23 Dec 2025
Biotech Cassava will pay $31.25M to end investor lawsuit from 2021 - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
